Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs

Incyte finally has some good news to share about one drug it’s discovered that’s not Jakafi — albeit one that doesn’t belong to it anymore.

FDA regulators have accepted capmatinib, an orphan and “breakthrough” MET inhibitor, for priority review. The honor technically goes to Novartis, which licensed worldwide development and commercialization rights to the drug back in 2009.